personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Ranibizumab versus bevacizumab in controlling progression of diabetic macular edema with cataract surgery

Session Details

Session Title: Vascular Diseases II

Session Date/Time: Friday 27/09/2013 | 11:00-12:30

Paper Time: 12:20

Venue: Hall F (Level 2)

First Author: A.Abdelghany EGYPT

Co Author(s):    E. Ghoniem   W. Ghobashi           

Abstract Details

Purpose:

To evaluate the efficacy of intravitreal injection of ranibizumab versus intravitreal injection of bevacizumab for management and controlling diabetic macular edema (DME) with cataract extraction using phacoemulsification

Setting:

Ophthalmology Department in Suez Canal University Hospital, Faculty of Medicine, Suez Canal University

Methods:

The study population included patients with DME associated with cataract, Pre operative best corrected visual acuity (BCVA) using LogMAR was taken and recorded then pre operative assessment with fluorescein angiography and central macular thickness (CMT) using optical coherence topography (OCT) was taken and recorded, then the patients were divided into two groups , for the first group both phacoemusification with posterior chamber in the bag intra-oclar lens (IOL) implantation and intravitreal injection of ranibizumab were done(Group A), for the second group both phacoemulsification with posterior chamber in the bag IOL implantation and intravitreal injection of bevacizumab were done (Group B). Post operative BCVA for each patient in each group was taken, also post operative assessment of central macular thickness with OCT was taken and recorded.

Results:

This study included 30 eyes of 30 patients, 15 in each group, and according to the results , in group A, there was 5 males and 10 females 8 patients did not undergo previous laser treatment while 7 patients underwent laser treatment, Group B included 7 males and 8 females, 9 patients did not undergo laser treatment while 6 patients underwent laser.In group A there was improvement of the mean CMT from 397.22 micron to 328.61 micron and improvement of BCVA (LogMAR) from 0.96 to 0.49. In group B the mean CMT improved from 401.8 micron to 379.08 micron,also BCVA (LogMAR)improved from 0.95 to 0.7

Conclusions:

From this study we concluded that OCT should be done pre operative to all diabetic patients who will undergo cataract surgery to assess CMT, also both ranibizumab and bevacizumab have an important effect in controlling DME with cataract surgery with higher efficacy for ranibizumab than bevacizumab.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy